Keywords: Allos Therapeutics, Folotyn, CHMP decision, T-cell lymphoma, Ph I

Allos Thera questions CHMP Folotyn decision; posts new data

Article | 31 January 2012

Print This

USA-based Allos Therapeutics, Inc. (Nasdaq: ALTH) says that it has submitted a request to the European Medicines Agency for a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in